top of page

CFH, Ltd.’s Clinical Trial

Inflammatory Marker Scores Significantly Improve With Use of CFH, Ltd.’s Full-spectrum Hemp Flower-Derived CBD

The new study shows CBD significantly reduces inflammatory marker scores by nearly 30 percent

Longmont, Colo., Dec. 15, 2021 -- A new clinical trial conducted by CBD bioscience company CFH, Ltd., in collaboration with Inflammatory Markers Laboratory, finds that a twice daily regime of 25 mg full spectrum hemp flower-derived CBD and terpene soft gels significantly reduces inflammatory marker scores by 29.4 percent.

This double-blind, placebo-controlled study measured the effect of CFH’s full-spectrum hemp flower-derived CBD and terpene preparation on chronic inflammation over the course of 6 weeks.

“Ongoing inflammation is a major cause of chronic disease and pain. Having tools like CBD that have been shown to help control the runaway inflammatory process is very important to managing the symptoms of inflammatory diseases,” says CFH’s Clinical Science Director Dr. Karen Hufnagl, DC, MS.

Participants in the CFH study were evaluated for levels of 11-Dehydro Thromboxane B2 via urine specimens by blinded scientists at the Inflammatory Markers Laboratory. The 11-Dehydro Thromboxane B2 compound increases with inflammation and inflammatory diseases such as heart disease, peripheral artery disease, stroke, diabetes, cancer, Alzheimer’s disease, obesity, and hypertension.

The group who received the full spectrum hemp flower-derived CBD and terpene soft gels showed a significant reduction of 29.4 percent in their inflammatory marker scores, while the group receiving the placebo saw no significant change in their inflammatory marker scores.

This clinical trial adds to the body of evidence showing the ability of CBD to support a normal inflammatory response, and in particular, documents the improvement of chronic inflammatory marker scores with the use of CFH’s full-spectrum hemp flower-derived CBD product, which also contains a robust and extensive profile of naturally occurring cannabinoids and terpenes.

“It’s pretty profound that as a daily regime, CBD is able to change the course of chronic inflammation and can positively impact the many illnesses related to inflammation,” says Dr. Hufnagl. “We are excited to continue contributing to the growing body of data that shows that CBD is safe and effective.”

Dr. Hufnagl is also the founder of In Avanti Health, a Functional Medicine Practice based in Colorado. With more than 20 years of experience, Dr. Hufnagl has one foot in everyday clinical practice and the other in product development and research. She specializes in thyroid and hormone imbalances and is also dedicated to helping athletes reduce pain and inflammation, maximize their recovery and performance, and reach new heights in their athletic pursuits.


About CFH, Ltd.

Founded in 2014, CFH, Ltd. is Colorado-based, vertically integrated CBD bioscience company and a leading supplier of CBD nationwide. CFH is committed to producing the highest quality full spectrum CBD and proprietary hemp strains that maintain the natural balance and proportion of the cannabinoids and terpenes present in hemp plants to provide optimal health benefits and efficacy. In addition to CBD as a major component, CFH's full spectrum hemp flower derived products contain an extensive profile of cannabinoids, terpenes and flavonoids. For more information on CFH, visit CFH.Ltd.


bottom of page